Skip to content

Compounds · Metabolic & weight · Treatment of obesity and type 2 diabetes

Retatrutide

On NovaEvumFull protocol

GGG Tri-agonist, GLP-1/GIP/Glucagon receptor agonist, LY-3437943

A triple agonist (LY3437943) hitting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. Trial data show strong weight loss and glucose control, exceeding many dual agonists; it is in Phase 3 testing for obesity and type 2 diabetes.

2 → 12 mg weekly, titrated

Research score 90/100. Reference only, not a prescription.

  • Appetite Suppression
  • Metabolic Enhancement
  • Blood Sugar Control
  • Weight Loss
  • GLP-1 Agonist
  • GIP Agonist
US status
Investigational
Approval
Phase 3 Clinical Trial
Evidence
Phase 3 trials ongoing (TRIUMPH program). Phase 2 data published in NEJM showing significant efficacy.
Research score
90 / 100
Indication
Obesity/Weight Management
Origin
USA
Source category
Digestive System
Status group
Investigational

Mechanism

GLP-1 activation drives glucose-dependent insulin release and satiety; GIP activation improves insulin sensitivity and nutrient storage; glucagon-receptor activation raises energy expenditure and fat metabolism, together producing added metabolic effect; structural changes allow once-weekly dosing.

Safety file

Profile similar to other incretin drugs; nausea and diarrhea are common and dose-related; a transient heart-rate increase has been observed.

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Gastrointestinal discomfort
  • Injection site reactions

Important: Reconstitute with bacteriostatic water only. Do not use sodium chloride (saline) bacteriostatic water. The wrong diluent can ruin the entire vial.

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water3 mL water
10 mg10 mg/mL5 mg/mL3.33 mg/mL
30 mg30 mg/mL15 mg/mL10 mg/mL
60 mg60 mg/mL30 mg/mL20 mg/mL

Works with anywhere from 1 mL to 3 mL of bacteriostatic water. Less water makes a stronger solution with smaller draws; more water dilutes it for larger, easier-to-measure draws. Always bacteriostatic water, never saline.

  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard titration (once weekly, subcutaneous)

  • Weeks 1 to 4: 2 mg once weekly
  • Weeks 5 to 8: 4 mg
  • Weeks 9 to 12: 6 mg
  • Weeks 13 to 16: 9 mg
  • Week 17 onward: 12 mg as the target maintenance dose
  • Hold each dose for the full 4 weeks before going up

If you do not need the full dose

  • Many people get strong results and stop climbing at 6 mg or 9 mg
  • There is no rule that you have to reach 12 mg
  • Stay at the lowest dose that is still working for you

Dosing detail

  • Start at 2 mg. In the phase 2 trial, a 2 mg start caused fewer stomach side effects than a 4 mg start, so the slow ramp is the whole point, not a formality.
  • The newer Phase 3 schedule (above) ramps 2, 4, 6, 9, 12 mg, each held 4 weeks, for the smoothest climb. The older Phase 2 trial jumped 2, 4, 8, 12 and skipped the 6 and 9 mg steps, which works but trades tolerability for speed.
  • Working range is roughly 4 mg to 12 mg weekly. 12 mg was the highest dose studied and gave the most weight loss.
  • Pick one day a week and keep it consistent, since the half-life is about 6 days.

Duration

  • Run it in 4-week blocks while titrating. Full programs run 16 to 24 weeks or longer. Many taper the dose down at the end rather than stopping cold, since stopping abruptly tends to bring weight back.

Notes

  • Inject subcutaneously into the stomach, love handles or thigh, rotating the site each week.
  • GI effects (nausea, early fullness, occasional constipation) hit most in the first week of a new dose and usually settle.
  • Keep protein intake high and stay hydrated as appetite drops, to hold onto muscle.
  • Splitting the weekly dose into two smaller shots smooths out side effects for some people.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard

NovaEvum vial

Worksheet

2 mL bacteriostatic water into 10 mg gives 5 mg/mL. A 2 mg weekly amount is 40 units; 4 mg is 80 units.

Catalog fill
10 mg
Typical water
2 mL
Route
Subcutaneous, once weekly
Cycle
Titration over months. Do not jump to a top-end amount in week one.
StepAmountFrequencyNotes
Start2 mgWeekly40 units at 5 mg/mL
Step4 mgWeekly80 units at 5 mg/mL
Later steps6, 9, then 12 mgWeekly, 4 weeks eachPast 1 mL at 5 mg/mL. Mix stronger (less water) or use a larger vial: 30 mg in 3 mL is 10 mg/mL, so 9 mg is 90 units
  • Gastrointestinal effects scale with the size of the jump, not just the absolute amount.
  • This compound is an investigational metabolic agonist. The worksheet does not diagnose, treat, or replace a clinician.
  • Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
  • Amounts on this sheet are reconstitution math for the vial, not a recommendation.